Peng Huimin, Zhang Rong, Zhang Hao
Department of Medicine Laboratory, The Hospital of Bayannaoer, Inner Mongolia Autonomous Rogion, Bayannur.
Department of Basic Medicine and Forensic Medicine, Medical College of Baotou, Baotou.
Medicine (Baltimore). 2020 Jun 12;99(24):e20742. doi: 10.1097/MD.0000000000020742.
The present study aimed to detect the A-kinase interacting protein 1 (AKIP1) expression in clear cell renal cell carcinoma (ccRCC) tumor tissues and adjacent tissues, and further investigate the correlation of tumor AKIP1 expression with clinicopathological features and survival profile in ccRCC patients.Totally 210 ccRCC patients who underwent resection were retrospectively reviewed, and their tumor and adjacent tissue specimens were acquired for immunohistochemical detection of AKIP1 expression. The survival data of patients were collected for overall survival (OS) assessment.AKIP1 was upregulated in ccRCC tumor tissues compared with adjacent tissues (P < .001). Tumor AKIP1 expression was positively associated with T stage (P = .019), N stage (P = .032), and TNM stage (P = .005) in ccRCC patients. According to AKIP1 expression in tumor tissues, all patients were grouped as AKIP1 low and high expression (AKIP1 high expression were further divided into AKIP1 high+, high++, and high+++ expression). OS was the lowest in the patients with AKIP1 high+++ expression, followed by those with AKIP1 high++ expression and AKIP1 high+ expression, and then patients with AKIP1 low expression (P < .001). Furthermore, multivariate Cox regression exhibited tumor AKIP1 high expression (P = .017), age (>60 years) (P = .030), pathological grade (G2/G3 vs G1) (P = .037), and TNM stage (II/III vs I) (P < .001) were independent predictive factors for decreased OS in ccRCC patients.AKIP1 presents potency to be a novel biomarker for tumor progression and prognosis surveillance in ccRCC.
本研究旨在检测透明细胞肾细胞癌(ccRCC)肿瘤组织及癌旁组织中A激酶相互作用蛋白1(AKIP1)的表达,并进一步探讨肿瘤AKIP1表达与ccRCC患者临床病理特征及生存情况的相关性。回顾性分析了210例行切除术的ccRCC患者,获取其肿瘤及癌旁组织标本,进行AKIP1表达的免疫组化检测。收集患者生存数据进行总生存期(OS)评估。与癌旁组织相比,ccRCC肿瘤组织中AKIP1表达上调(P<0.001)。ccRCC患者肿瘤AKIP1表达与T分期(P = 0.019)、N分期(P = 0.032)及TNM分期(P = 0.005)呈正相关。根据肿瘤组织中AKIP1表达情况,将所有患者分为AKIP1低表达组和高表达组(AKIP1高表达组进一步分为AKIP1高+、高++和高+++表达组)。AKIP1高+++表达组患者的OS最低,其次是AKIP1高++表达组和AKIP1高+表达组,然后是AKIP1低表达组患者(P<0.001)。此外,多因素Cox回归分析显示,肿瘤AKIP1高表达(P = 0.017)、年龄(>60岁)(P = 0.030)、病理分级(G2/G3 vs G1)(P = 0.037)及TNM分期(II/III vs I)(P<0.001)是ccRCC患者OS降低的独立预测因素。AKIP1有望成为ccRCC肿瘤进展和预后监测的新型生物标志物。